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Abstract
Background: Complement C2 deficiency is the most common genetically determined complete complement
deficiency and is associated with a number of diseases. Most prominent are the associations with recurrent serious
infections in young children and the development of systemic lupus erythematosus (SLE) in adults. The links with
these diseases reflect the important role complement C2 plays in both innate immunity and immune tolerance.
Infusions with normal fresh frozen plasma for the treatment of associated disease have demonstrated therapeutic
effects but so far protein replacement therapy has not been evaluated.
Results: Human complement C2 was cloned and expressed in a mammalian cell line. The purity of recombinant
human C2 (rhC2) was greater than 95% and it was characterized for stability and activity. It was sensitive to C1s
cleavage and restored classical complement pathway activity in C2-deficient serum both in a complement
activation ELISA and a hemolytic assay. Furthermore, rhC2 could increase C3 fragment deposition on the human
pathogen Streptococcus pneumoniae in C2-deficient serum to levels equal to those with normal serum.
Conclusions: Taken together these data suggest that recombinant human C2 can restore classical complement
pathway activity and may serve as a potential therapeutic for recurring bacterial infections or SLE in C2-deficient
patients.
Background
Our understanding of the role of complement in human
disease is the result of numerous studies in recent years
focused on complement’s mechanism of action. This has
resulted in achieving important information on the role
of complement as a major mediator and effector mechan-
ism in diseases of immune and non-immune pathogen-
esis. Complement is not only important for protection
against microorganisms, but also contributes to the
pathophysiology of a number of autoimmune diseases.
Progress regarding the biological role of complement
has been made by studying disease associations in
patients with inherited complement protein deficiencies
[1]. Genetic deficiencies of complement components are
a common denominator of immune and infectious dis-
eases. Deficiencies of complement components of the
classical activation pathway, C1, C2 and C4, all lead to
increased susceptibility to bacterial infections [2] and
increased risk of developing autoimmune disease, parti-
cularly systemic lupus erythematosus (SLE) [3]. The
complement system consists of more than 30 soluble
and membrane proteins and constitutes an important
mediator of host defense against foreign pathogens.
Complement component C2 functions as a key regulator
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any medium, provided the original work is properly cited.in the early activation phase of the classical pathway and
participates in the formation of the classical pathway C3
convertase C4b2a [4]. C2 is also a critical component of
the lectin pathway. Specifically, when mannose-binding
lectin (MBL) or ficolins in complex with MBL-asso-
ciated serine protease (MASP) molecules bind to rele-
vant carbohydrate molecules, this leads to activation of
MASP-2 which then may cleave both C2 and C4
thereby forming the same C3 convertase as in classical
pathway activation [5]. Thus, C2 is an important com-
ponent of both the classical and the lectin pathways of
complement activation and is involved in first line
defense against microbial infection that is essential for
detection and clearance of the invading pathogens [6].
Complement C2 deficiency is the most common
genetically determined complete complement deficiency
with a prevalence estimated to be approximately
1:20,000 in individuals of Caucasian ancestry [3], making
it a clinically important immune deficiency [7]. The defi-
ciency is, in the majority of cases, caused by homozygos-
ity for C2 genes having deletions in exon 6, resulting in
complete absence of C2, or in some cases caused by
other C2 gene mutations [8,9]
The alternative activation pathway, which is C3
dependent, is generally intact in C2 deficiency and can
trigger formation of the membrane attack complex
(MAC) independently of C2 [4]. However, in the
absence of C2, C3 is, in many situations, not efficiently
cleaved resulting in a limited deposition of C3 fragments
on immune complexes and on the surface of apoptotic
cells. Circulating apoptotic cells become a source of self
antigen for auto-antibodies that participate in the forma-
tion of immune complexes. The immune complexes are
deposited throughout the body, potentially causing loca-
lized inflammatory reactions in joints and kidneys, and
ultimately leading to renal disease from chronic activa-
tion of the complement system [10].
In this study, we considered C2 replacement as a ther-
apeutic target to explore the feasibility of restoring the
complement pathway in cases of C2 deficiency. It has
been previously proposed that purified human C2 could
restore classical and lectin complement pathways and
hemolytic activity ex-vivo in serum collected from C2-
deficient patients [11]. Two case histories have been
described where regular infusions of fresh frozen plasma
were beneficial in patients with C2-deficiency and SLE;
this benefit was ascribed to the C2 contained in the
fresh frozen plasma [12,13]. Therefore, we hypothesized
that recombinant human complement component C2
(rhC2) could restore complement activity in serum from
C2-deficient patients. To test this hypothesis we have
expressed and purified rhC2 and assessed complement
activation in vitro. To our knowledge this is the first
report of proof of concept for treating C2 deficiency
with recombinant human C2.
Results
Protein Cloning and Expression
The rhC2 was highly expressed in human cells and
shown to be purified very efficiently by a 2-step column
chromatography process (Figure 1A) based on a modifi-
cation and improvement of a procedure previously
described [14,15] (some cleaved products of rhC2, C2a
and C2b, are present in the conditioned media as a
result of endogenous proteases produced by the cells).
After purification, a major band, representing rhC2, is
visible by Coomassie staining as well as a smaller band,
C2b, the inactive part of the cleaved C2, which co-puri-
fies with the full length protein and constitutes a minor
impurity. C2a is completely removed during the purifi-
cation process. An early report on C2 analysis indicates
that the mature protein has eight glycosylation sites
[16]. To determine post-translational modification of
rhC2 we performed a glycodigestion with Peptide N-
glycosidase and show that rhC2 is glycosylated when
produced in human cells (Figure 1B). Neuramidase
digestion of the protein also demonstrated the presence
of sialic acid on rhC2 (Figure 1C), which may result in
greater stability of the protein in serum [17]. By multi
angle static light scattering (MALS) the weight average
molar mass (Mw) of the full length rhC2 including
glycosylation was determined to be 99,800 g/mol
(Figure 2). The number average molar mass (Mn) can
also be determined by SEC-MALS, with the ratio Mw/
Mn providing a measure of polydispersity. The polydis-
persity index of rhC2 is 1.00054, indicating narrow mass
distribution. The line in figure 2 represents the differen-
tial refractive index (dRI) versus elution time, indicating
the elution of rhC2. The data points in figure 2 are the
molar mass determined from the light scattering inten-
sity using the concentration measured by dRI for the
glycoprotein complex, and the absorbance at 280 nm for
the protein component. The molar mass of the protein
component was 84,000 g/mol and the difference in the
two masses was the weight of the modifiers (glycosyla-
tion) which was 15,800 g/mol. The 84,000 g/mol mass
of the protein without any modifiers was consistent with
the expected molecular weight calculated from the pro-
tein sequence of ~ 82000 kDa. The purity of rhC2
determined by size exclusion chromatography (SEC) was
greater than 95% (Figure 3A) with minor impurities
consisting mainly of C2b, characterized also by MALDI-
TOF analysis (data not shown).
Differential scanning calorimetry (DSC) showed a single
temperature induced unfolding transition with a tempera-
ture midpoint (Tm) of 53.4°C (Figure 3B). The ratio of the
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(ΔHvH) was 2.8, consistent with the three structural
domains of rhC2 unfolding in a single transition. Surveys
comparing Tm and ΔH at various pH values and salt con-
centrations indicate that rhC2 is most stable at pH 6.5 and
150 mM NaCl (data not shown).
rhC2 is cleaved by C1s and is active in C2 depleted serum
As a first step in the activation of the classical comple-
ment pathway, complement protein C1q binds to anti-
bodies and triggers the activation of C1r and C1s.
Activated complement factor C1s cleaves C2 and C4 so
they can form the C3 convertase thereby triggering the
terminal portion of the complement cascade [15].
Therefore, in order for C2 to be fully functional, it must
first be cleaved by C1s. Cleavage of C2 results in release
of C2a (70 kDa) which in association with C4b serves as
the C3 convertase. A smaller protein, C2b (30 kDa), is
also released following cleavage by C1s. To determine
that rhC2 exhibited the correct functional conformation,
purified protein was incubated with purified C1s and
the resultant proteins visualized by SDS-PAGE and Coo-
massie staining (Figure 4A). Results from these studies
show that rhC2 is cleaved by C1s, releasing C2a and
C2b proteins of the correct molecular weight. C2 puri-
fied from human plasma was included as a positive con-
trol. These data suggest that rhC2 forms the correct
functional conformation to activate the classical comple-
ment pathway.
To determine whether rhC2 was able to restore com-
plement activation through the classical pathway, puri-
fied recombinant protein was diluted in affinity depleted
C2-deficient serum (0 - 40 μg/ml) and tested using the
Total Complement (3-Pathway) ELISA. The 3-pathway
ELISA measures the ability of complement proteins in a
given serum sample to activate the classical, lectin or
alternative pathway based on specific antigens used to
trigger each pathway of the cascade. Results show the
specific reconstitution of the classical and lectin comple-
ment pathways when rhC2 was added to the C2-
depleted serum but these pathways were not activated
in the absence of rhC2 (Figure 4B). An rhC2 concentra-
tion of 3 μg/ml restored > 50% classical pathway activ-
ity, with 100% activation at 12 μg/ml. As expected, the
alternative pathway, which is independent of C2, was
activated by C2-depleted serum. An irrelevant protein
(a transferrin fusion protein) with similar MW was used
as negative control and did not activate the complement
pathway.
C3 deposition on bacterial pathogen Streptococcus
pneumoniae
Susceptibility to encapsulated bacterial pathogens such
as Streptococcus pneumoniae, Neisseria meningitidis
and Haemophilus influenzae is a hallmark of C2 defi-
ciency, particularly in young children (≤ 2 years) (2).
The classical complement pathway plays a key role in
the clearance of these pathogens through antibody and
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Figure 1 Expression, purification and post-translational modification of rhC2. A) Coomassie stained SDS-PAGE gel of rhC2 at different
stages of the purification process. Each lane contains 0.5 μg protein: Lanes: 1. Molecular weight marker, 2. conditioned media, 3. Sepharose pool,
4. purified C2. B) rhC2 glycodigestion with Peptide N-glycosidase (PNGase-F) shows removal of carbohydrates from the protein backbone. Lanes:
1. rhC2 + 1 hour PNGase-F, 2. rhC2 untreated 1 hour, 3. rhC2 + overnight PNGase-F, 4. rhC2 untreated overnight. C) Neuramidase digestion of
rhC2 reveals sialic acid removal after digestion of the protein. Lanes: 1. rhC2 + 1 hour Neuramidase, 2. rhC2 untreated.
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vation by antibodies to encapsulated bacterial patho-
gens results in the deposition of C3b on the surface of
the bacterium in association with C3 cleavage by the
C4b2a complex. In the absence of C2, only C4b is
bound to the bacterial cells as a result of the classical
pathway activation initiated by the specific antibodies.
The addition of 25 μg/ml rhC2 or C2 purified from
plasma to C2-deficient serum increased the C3d
deposition on Streptococcus pneumoniae to levels simi-
lar to those using a pool of normal serum (Figure 5A).
Thus, we could demonstrate that addition of C2 to
C2-deficient serum highly increased the C3 fragment
deposition on the bacteria. Figure 5B shows flow cyto-
metry plot of C3 fragment deposition using a serum
sample from a C2-deficient patient serum before and
after restitution with rhC2
Reconstitution of classical pathway activity in serum from
C2-deficient patients
Considering rhC2 as a therapeutic alternative for C2
deficiency-associated diseases, it was important to test
the concept in serum collected from human patients
homozygous for C2 deficiency. We have used the
3-pathway ELISA that measures complement cascade
activation as well as a hemolytic assay that measures
classical pathway activity by determining the ability of
serum complement proteins to bind to antibody-coated
sheep red blood cells. Successful activation of the classi-
cal pathway results in formation of the MAC and red
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Figure 2 Analysis of rhC2 glycosylation by SEC-MALS. rhC2 was
eluted from a Tosoh Super SW3000 size exclusion column and
monitored by normalized differential refractive index (─) and
absorbance at 280 nm versus time. Molar mass was analyzed by
multi angle light scattering following the total mass by differential
refractive index (□), and protein mass by absorbance at 280 nm (Ο).
The molar mass contributed by glycosylation is plotted as the
difference between the total mass and the mass of the protein (Δ).
The average molar mass determined for the total is 99.8 kDa, the
protein 84 kDa, and the carbohydrate 15.8 kDa.
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Figure 3 Biochemical analysis of rhC2. A) Chromatogram representing the purity of rhC2 by size exclusion chromatography: purity was
calculated to be ~96%. The % area (% purity) was quantified using Exponential Skim Integration of the Empower software. B) Differential
scanning calorimetry: 400 μg/ml of protein were loaded in the calorimetry cell and heated at a rate of 60°C/hour. The excess heat capacity vs.
temperature shows a single unfolding transition with a midpoint at (Tm) of 53.4°C.
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Page 4 of 10blood cell lysis. Serum from six different C2-deficient
patients was reconstituted with rhC2 and tested in the
3-pathway ELISA according to the manufacturer’s
instructions and three C2-deficient sera were also ana-
lyzed by the hemolytic assay [18]. In addition, rhC2 was
titrated and tested in C2-deficient serum from patients
in the 3-pathway ELISA to investigate the minimum
amount of protein needed to restore classical pathway
activity to levels similar to those in pooled normal
human serum.
Results from the 3-pathway ELISA and hemolytic
assay show that rhC2 restores the capacity of C2-
rhC2 (µg/ml)
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Figure 4 rhC2 characterization. A) Cleavage of rhC2 by complement protease C1s. Lanes: 1. High molecular weight marker, 2. Low molecular
weight marker, 3. rhC2 undigested, 4. rhC2 (25 μg/ml) digested with C1s, 5. rhC2 (50 μg/ml) digested with C1s, 6. plasma purified C2, 7. plasma
purified C2 (25 μg/ml) digested with C1s, 8. Low molecular weight marker, 9. High molecular weight marker. B) Reconstitution of complement
activity as measured by complement activation ELISA by rhC2 in C2 affinity depleted human serum. Normal human serum was used as standard
(100%). Dose response of rhC2 in serum shows activation of the classical pathway at a concentration as low as 3 μg/ml. As negative control, an
irrelevant protein (C) was run to confirm specificity of the assay to rhC2. Data represent the mean ± SD of three independent experiments.
Figure 5 Effect of rhC2 on deposition of C3 fragment on the surface of Streptococcus pneumoniae analyzed by flow cytometry.T h e
bacteria were incubated with C2 deficient (C2D) serum from patients, C2D serum with (25 μg/ml) rhC2 or plasma purified C2. Pooled normal
human serum (NHS) was used as control. A) Results with 3 different C2D sera expressed as mean fluorescence index (MFI) ratio between the
recorded fluorescence with anti-C3d antibody and the fluorescence obtained with the isotype control antibody. B) Flow cytometry plots
showing MFI of C3 fragment deposition with one C2D serum (C2D-3) before and after restitution with rhC2.
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Page 5 of 10deficient patient serum for classical pathway activation
enabling the formation of the MAC (Figures 6A and
6B). Titration of rhC2 revealed that a concentration of
3.0 - 6.0 μg/ml was sufficient to activate the classical
complement pathway to ≥70% activity of normal human
serum in different C2-deficient patient sera (Figure 6A).
As a reference, normal human serum from healthy indi-
viduals contains 16 - 40 μg/ml of circulating C2. No
activation of the lectin pathway was observed in most of
these patient sera due to low serum levels of MBL
(Table 1).
Discussion
In this study we provide proof of concept that rhC2
produced in human cells could be considered as an
alternative treatment for C2-deficient diseases. This
concept was originally formulated by Ruddy et al [11],
where in an ex-vivo experiment they reconstituted
hemolytic activity of C2-deficient serum collected from
a patient by adding C2 purified from normal human
serum. We have expanded this concept further and
have demonstrated that rhC2 can be expressed in high
quantities from human cells. We have prepared highly
purified rhC2, shown that it undergoes post-
translational modification and that it is very stable.
rhC2 is cleaved in-vitro by C1s protease generating the
active subunit of C2 (C2a) necessary to form the C3
convertase C4b2a and more importantly, it restores
the classical and lectin pathways in C2-depleted and
C2-deficient serum at different concentrations. The
fact that we were able to show normalization of
rhC2 (µg/ml)
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Figure 6 rhC2 restores classical pathway complement activity in C2-deficient patient serum. A) Representative titration of rhC2 in serum
from a C2-deficient patient and measurement of complement pathway activity by complement activation ELISA. “C’ denotes inclusion of an
irrelevant protein used to confirm specificity of the assay to rhC2. Data represent the mean ± SD of three independent experiments. B) rhC2
restores classical pathway hemolytic activity in C2-deficient patient sera. When rhC2 (25 μg/ml) was added to the sera from 3 different patients,
complement activation was triggered and hemolysis observed. Samples no. 1 Normal human serum, 2 - 4 C2-deficient patient sera, 5-7 the
C2-deficient patient sera restituted with rhC2 (25 μg/ml), 8 C2-deficient serum restituted with plasma purified C2 (25 μg/ml). Alternative pathway
of hemolysis as a control is also shown.
Table 1 Restitution of Classical (CP), Lectin (LP) and
Alternative pathway (AP) activation in serum from 6
C2-deficient patients by addition of rhC2
Restituted serum
a
Patient no.
CP LP
c AP
1 +++
b ± +++
2 +++ - +++
3 +++ ± +++
4 +++ + +++
5 +++ ++ +++
6 +++ - +++
arhC2 was added to C2-deficient serum, final concentration 25 μg/ml.
bComplement activation tested by ELISA. +++ = 100% activation, ++ = 50%,
+ = 20%, - = no activation.
cLP activity reflects the MBL concentration governed by MBL genotype.
Patient 5 is homozygous for the wild-type structural gene variant (genotype
A/A), while the other patients are heterozygous for this allele.
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μg/mL) that are lower than those typically observed in
normal human serum (16-40 μg/mL) is in accordance
with the reports that the heterozygous C2-deficiency
state is not a risk factor for disease [3], and confirms
that the rhC2 is fully functional.
To our knowledge this is the first report to date
describing the production, purification and functional
activity of rhC2 produced in human cells. In previous
reports C2 was either from plasma of human or animal
origin or from mouse L-cells or monkey COS cells
[14,19-23]. The advantage of expressing C2 in human
cells is that it may result in a more naturally glycosy-
lated protein; most likely very similar or identical to the
human C2 secreted in normal individuals, which is, in
our opinion, an important consideration for the devel-
opment of a therapeutic protein. We have also shown
that rhC2 restores the classical pathway activation
in-vitro in C2-deficient serum obta i n e df r o ms i xd i f f e r -
ent patients. The use of C2-deficient human serum
represents the proof of concept for therapeutic use of
rhC2 as an alternative therapy for C2 deficiency-asso-
ciated diseases. Restoration of the classical pathway in
human C2-deficient serum with rhC2 could be an
important step, for instance, in treating C2-deficient
SLE patients refractory to current therapies. Interest-
ingly, it has been previously reported in two patients
that infusion of normal fresh frozen plasma as a source
of complement C2 provided therapeutic benefit [12,13].
Immunological studies performed in one of these
patients revealed that these infusions led to increased
serum C2 levels, increased hemolytic activity, decreased
immune precipitation and decreased circulating immune
complexes [13,24]. Although it has been argued that the
observed clinical effects of fresh frozen plasma were a
result of multiple components in the plasma (Factor B,
immunoglobulin, MBL) other than C2, it has been
demonstrated that treatment with IgG only in the
amount corresponding to one course of plasma infusion
[24] did not have any beneficial effect, suggesting that
the key player in promoting complement activity
through the classical pathway, was C2 alone. In addition,
infusion of rhC2 may decrease the risk of developing
adverse reactions compared to plasma infusion as
plasma contains many proteins that may trigger differ-
ent reactions in patients.
The therapeutic use of rhC2 could also be considered
in the case of C2-deficient individuals with recurrent or
invasive bacterial infections. It has been shown that C2
deficiency is associated with increased susceptibility to
recurrent infections by encapsulated bacterial pathogens
such as Streptococcus pneumoniae [7,25,26]. Comple-
ment activation resulting in opsonization of the bacteria
with C3 fragments is an important defense mechanism
which is impaired in C2 deficiency [27]. Therefore, we
could envision rhC2 as an adjunct therapy to antibiotics,
with the rhC2 facilitating phagocyte-mediated clearance
of the pathogen by enabling full complement cascade
activation.
Blood protein replacement therapy is well established
in some clinical situations, for example, intravenous
immunoglobulin in patients with antibody deficiencies
or coagulation factors in the hemophilias and specific
lysosomal hydrolases in lysosomal storage diseases [28].
Drotrecogin alpha, a recombinant form of activated
p r o t e i nC ,i sa p p r o v e df o ru s ei ns e p s i sa n dD i f f u s e
Intravascular Coagulation. The only complement repla-
cement therapy already established is in hereditary
angioedema caused by C1-inhibitor deficiency. Plasma-
derived C1-inhibitor is shown to be an efficient
treatment [29] and recombinant C1-inhibitor is under
clinical evaluation [30]. Another complement protein
that has been tried as replacement therapy is MBL in
patients with MBL deficiency and clinical disease,
related to the deficiency. Plasma-derived MBL has been
used [31] and recently recombinant MBL was shown to
successfully restore the MBL activation pathway in vivo
[32]. Thus, all together these examples suggest that C2
replacement therapy could be considered for further
evaluation of possible therapeutic use in humans.
Recombinant human proteins offer many benefits over
purified products from pooled human plasma, such as a
lower risk of transmission of infectious diseases and
higher batch-to-batch consistency [33]. Therefore, it was
important to show that rhC2 can substitute for endo-
genously produced C2 in its immune and anti-infective
effects. The present report shows that rhC2 is fully
functional in vitro and can be considered for protein
replacement therapy in C2 deficiency-associated
diseases.
Conclusions
We have demonstrated that a biochemically well charac-
terized recombinant human complement component C2
produced in a human cell line restores classical comple-
ment pathway activation in vitro,i ns e r u mf r o mC 2 -
deficient patients. Establishing efficacy in specific animal
models for SLE and infectious diseases will further vali-
date this concept; although the present study provides
the first evidence for protein replacement therapy as a
treatment of diseases related to C2 deficiency.
Methods
Cell culture and protein expression
Complement component C2 (NM_000063) was cloned
from a liver cDNA library (Invitrogen, Carlsbad, CA),
and inserted into a plasmid carrying a collagen promo-
ter (pX804) or into pCep4 (Invitrogen, Carlsbad, CA).
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Page 7 of 10HT1080 cells (CCL-121, ATCC, Manassas, VA) were
grown and maintained in CD media (50% CD-CHO and
50% CD-293) (Invitrogen, Carlsbad, CA) at 37°C in a 5%
CO2 incubator. Stable transfections were carried out
using electroporation (450 V with 250 μF of capacitance
and 30 μg of plasmid DNA suspended in 750 μl1 ×
PBS). 293-F cells (Invitrogen, Carlsbad, CA) were grown
in Freestyle 293 media (Invitrogen, Carlsbad, CA) con-
taining GlutaMAX. Cells were transiently transfected
using a polyethylenimine (25 kD, Polysciences, Warring-
ton, PA) to DNA ratio of 3:1 and were supplemented
with 2.5 mg/ml Primatone (MP Biomedicals, Solon, OH)
at 24 hours. Seventy-two hours after transfection condi-
tioned media enriched in rhC2 was harvested from a 25
liter wave bioreactor (GE Healthcare, Piscataway, NJ)
and then processed for purification.
Protein purification and biochemical characterization
A two-step purification process was developed for rhC2.
First a SP Sepharose Fast Flow resin column (GE
Healthcare, Piscataway, NJ) was used to capture the pro-
tein from harvest medium. The binding capacity of the
SP resin was experimentally determined by ELISA to be
0.37 mg rhC2 per ml of SP resin. Protein was then
eluted from the column and samples from collected
fractions were analyzed by BCA Protein Assay Kit,
(Pierce, Rockford, IL) to determine protein concentra-
tion and visualized by Coomassie staining (GelCode
Blue Stain Reagent, Pierce, Rockford, IL) of 8-16% tris-
glycine SDS-PAGE gels under reducing conditions (Invi-
trogen, Carlsbad, CA). The fractions containing full
length rhC2 (102 kDa) were pooled and further purified
over a Heparin Sepharose Fast Flow resin column (GE
Healthcare, Piscataway, NJ). A binding capacity of 1 mg
of total protein by BCA assay per ml of Heparin resin
was used. Eluted fractions were assessed as described
above and those containing rhC2 were pooled, concen-
trated and buffer-exchanged into storage buffer (10×
PBS diluted to 1× in water and adjusted to pH 7). Forty
five liters of harvest media from the WAVE bioreactor
yielded 228 mg of purified rhC2. The resultant rhC2
protein was confirmed by N-terminal sequencing (Mayo
Proteomics Research Center, Mayo Clinic College of
Medicine in Rochester, MN) and was assessed for purity
using size exclusion chromatography. Purified rhC2
(5 μg) was separated on a size exclusion chromatogra-
phy (SEC) column (Tosoh SuperSW 3000, 10,000-
500,000 Da, Tosoh, Montgomery, PA) with 25 mM
sodium phosphate, pH 6.5 and 500 mM sodium chloride
in MilliQ water as the mobile phase with a flow rate of
0.15 ml/min. The chromatogram was quantified using
Exponential Skim Integration of the Empower software
(Waters, Milford, MA). Using this procedure, the resul-
tant rhC2 was determined to be 96% pure. The
molecular weight and hydrodynamic radius of the major
peak seen on size exclusion chromatography for rhC2
was analyzed using a multi angle static and dynamic
light scattering system from Wyatt Technologies (Santa
Barbara, CA) in conjunction with size exclusion chro-
matography method described above with the following
modifications: the pH of the light scattering mobile
phase buffer was increased to pH 7.0, the flow rate was
increased to 0.3 mL/min, and 10 μg of rhC2 diluted
(1:10) in light scattering mobile phase buffer.
Glycodigestion was performed to determine the pre-
sence of carbohydrates and sialic acid. Two micrograms
of rhC2 was used for glycodigestion, for carbohydrate
determination the protein was incubated for 1 hour and
overnight at 37°C with Peptide N-glycosidase in reaction
buffer (New England Biolabs, Beverly, MA). For sialic
acid determination, rhC2 was incubated for 1 hour at
37°C with neuraminidase in reaction buffer (New Eng-
land Biolabs, Beverly, MA). SDS-PAGE was performed
with 250 ng of sample digested with above enzymes,
loaded on 8-16% gel and visualized by Western blot.
Thermal stability of rhC2 was assessed with differential
scanning calorimetry using a MicroCal VP-DSC (GE
Healthcare, Piscataway, NJ) with 400 μl buffer (25 mM
sodium phosphate, 500 mM sodium chloride) per buf-
fer/sample pairs in 96 deep well plates loaded in the
CapVP-DSC autoloader. Data were collected with the
calorimeter scanning from 10 to 100°C at a rate of
60°C/hour.
A sandwich ELISA was developed to allow specific
quantitation of rhC2 during purification. The wells of a
96-well Nunc Immuno plate (Nalge Nunc International,
Rochester, NY) were coated with 100 μlo f1μg/ml anti-
human C2 goat polyclonal antibody (R&D systems,
Minneapolis, MN) in 50 mM sodium bicarbonate, pH
9.6. The plate was sealed and incubated overnight at RT.
The next morning the wells were washed 3 times with
ELISA Wash Buffer (0.1% Tween-20 in PBS), then 300 μl
of Blocking Buffer (PBS, 0.05% Tween-20, 2% BSA) were
added to each well and the plate was incubated for
1 hour at 37°C. Following the incubation, blocking buffer
was removed, 100 μl volume of samples and standards
(pre-diluted in blocking buffer) were added to the plate,
and the plate was incubated for 1 hour at 37°C. Following
incubation, the plate was washed as described above, the
secondary antibody, a mouse anti-human C2 monoclonal
a n t i b o d y( A b c a m ,C a m b r i d g e ,M A ) ,w a sa d d e dt oa l l
wells at a final concentration of 1 μg/mL (100 μlp e r
well) and the plate was incubated for 1 hour at 37°C then
washed. After washing, 100 μl of 100 ng/ml of HRP-
conjugated anti-mouse antibody (Promega, Madison, WI)
was added to each well and the plate was incubated for
1 hour at 37°C then washed. Finally, 100 μlo ft h ec o m -
plete Peroxidase EIA Substrate Kit (BioRad, Hercules,
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20 min at 37°C. The reaction was stopped by adding
100 μlo f2NH 2SO4 to each well and the plate was read
at 450 nm on a Molecular Devices plate reader equipped
with SoftMax Pro software. The standard curve had a
dynamic range from 200 ng/ml to 3 ng/ml prepared by
serially diluting C2 purified from human serum (R&D
systems, Minneapolis, MN).
Cleavage of rhC2 by C1s
rhC2 and purified C2 from human plasma at a concen-
tration of 25 μg/ml and 50 μg/ml, respectively were
incubated with active C1s for 1 h at 37°C in veronal buf-
fered saline with 0.15 mM Ca
2+ and 0.5 mM Mg
2+
(VBSCaMg) at a concentration of 70 μg/ml to induce
complete cleavage of C2. C1s was produced and purified
as described by Arlaud G.J. et al, [34]. The proteins
were then analyzed by SDS-PAGE using NuPAGE® 4-
12% Bis-Tris Gel, NuPAGE MES SDS running buffer
(Invitrogen Carlsbad, CA) and visualized by Coomassie
staining (Bio-Rad, Hercules, CA).
Restoration of complement classical pathway
The activity of purified rhC2 was determined using the
Total Complement (3-pathway) ELISA (Alpco, Salem,
NH) according to manufacturer instructions. Pooled
human serum that had been stripped of C2 by affinity
purification (EMD BioSciences, San Diego, CA) was
reconstituted with various concentrations of rhC2 and
tested. The functional activity of rhC2 was also ana-
lyzed by hemolysis in gel assays that detect deficiencies
in the classical and alternative pathways of comple-
ment activation as well as deficiencies in the terminal
sequence. In the classical pathway assay antibody-
coated sheep red blood cells were suspended in 0.6%
agarose (SeaKem
R ME agarose, Cambrex BioScience
Rockland Inc., Rockland, ME) in the presence of Ca
2+
and Mg
2+. Guinea pig erythrocytes in the presence of
Mg
2+ and EGTA were used similarly in the assay for
the alternative pathway. Samples were added to holes
punched in the agarose in 5 μl volumes and allowed to
diffuse into the agar in moist atmosphere at 4°C for
18 hours and then at 37°C for 2 hours for the lytic
reaction to proceed [18].
Deposition of C3 fragments on bacteria
Streptococcus pneumoniae 23F, obtained from Statens
Serum Institut (Copenhagen, Denmark) were cultured
on blood agar plates and then grown in Todd-Hewitt
broth until log-phase was reached. The bacteria were
harvested, washed in 0.15 M NaCl and killed by adding
0.8% glutaraldehyde in 0.15 M NaCl for 20 min. The
killed bacteria were stored in small aliquots at -80°C
until use. To measure C3 deposition on the bacteria,
serum (100 μl), diluted 1/20 in VBSCaMg, was added
to 2.5 μl bacteria and incubated for 30 min at 37°C
with continuous agitation. The incubation was stopped
by adding 500 μlo fi c e - c o l dV B S C a M g .T h eb a c t e r i a
were washed (centrifugation 2,880 × g, 15 min) and
then 100 μl of anti-C3d (Quidel, Santa Clara, CA),
diluted 1/100 in VBSCaMg was added followed by an
incubation at 4°C for 30 min. After the incubation the
bacteria were washed and resuspended in 100 μl
VBSCaMg and 5 μl FITC-conjugated polyclonal F(ab’)2
rabbit anti-mouse immunoglobulins (DakoCytomation,
Glostrup, Denmark) was added. The tubes were then
incubated for 30 min at 4°C. Prior to analysis by flow
cytometry (Epics XL-MCL Beckman-Coulter, Fullerton,
CA), the bacteria were washed once and resuspended
in 500 μlV B S C a M g .
C2-deficient patients
Sera from 6 patients with homozygous C2 deficiency
were used. Studies on the C2-deficient patients were
approved by the Lund University Research Ethics Com-
mittee (LU 513-01) and written informed consent was
obtained for each patient. The 6 individuals all had type
I C2 deficiency as ascertained by DNA analysis, and had
been reported earlier [7]. MBL genotypes had also been
determined as reported [26]. Only one of these patients
was homozygous for the wild-type variant of the struc-
tural MBL2 gene giving rise to high concentration of
MBL and lectin pathway activity. The others were het-
erozygous for this allele and depending on promoter
variants they showed lower concentrations of serum
MBL to varying degrees.
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